Compare skeletal age (Greulich-Pyle / Tanner-Whitehouse) to chronological age and predict adult height using the Bayley-Pinneau method. Essential for short stature, precocious puberty and growth disorder workup.
EasyClinic plots successive heights on IAP 2015 charts, flags < 4 cm/year growth velocity, and generates an endocrine referral letter with all anthropometry — no Excel sheets needed.
Bone age (skeletal age) is an estimate of biological maturity based on the appearance and fusion of ossification centres in the hand and wrist. It is read off a standard X-ray of the non-dominant hand and wrist. Two systems are used:
The IAP Growth Charts Committee recommends bone age assessment as part of any short-stature evaluation. Practical Indian considerations:
The Bayley-Pinneau method divides current height by the fraction of adult height typically achieved at the given bone age. Limitations:
For routine outpatient practice, Greulich-Pyle is faster and acceptable. Use TW3 when ±6-month precision matters (e.g., GH trial monitoring, GnRH analogue decisions). AI-based bone age readers (e.g. BoneXpert) are being deployed at AIIMS and a few corporate hospitals.
A delay or advancement of > 2 years compared to chronological age (or > 2 SD) is significant and warrants endocrine evaluation. Smaller deviations (1-2 yr) may be normal variation, especially in constitutional delay of growth and puberty (CDGP).
IAP 2015 charts (Khadilkar et al.) are based on contemporary Indian middle/upper-SES urban children and should be the primary reference. WHO charts often misclassify Indian children as short. Bone age atlases remain Western — interpret with caution and ethnic adjustment.
Recombinant human GH (somatropin) costs approximately ₹15,000-25,000 per month at standard pediatric dose (0.18-0.3 mg/kg/week). Generic biosimilars (e.g., Eutropin, Norditropin biosim) are available. Total course over 4-7 years often ₹15-25 lakh. Government schemes (PMJAY) cover GH for documented GHD in some states.
Yes, approximately. Menarche typically occurs at bone age 13-13.5 years in girls. Bone age advancement closer to 13 in a girl with thelarche helps predict imminent menarche, useful when planning GnRH analogue therapy for central precocious puberty.
EasyClinic plots height, weight, BMI, bone age vs IAP and WHO charts on a single dashboard — auto-flags crossing percentiles and prompts endocrine referral.
Choose the plan that fits your practice — cancel anytime.
DOCTORSCRIBE
₹999
/month
EASYCLINIC
₹1,999
/month